These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33376084)

  • 21. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.
    Khunti K; Wolden ML; Thorsted BL; Andersen M; Davies MJ
    Diabetes Care; 2013 Nov; 36(11):3411-7. PubMed ID: 23877982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
    Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
    Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.
    Peng XV; Ayyagari R; Lubwama R; Shi L; Price-Haywood EG; Hollander P; Fonseca V
    Diabetes Ther; 2020 Apr; 11(4):995-1005. PubMed ID: 32112204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables.
    Ji LN; Lu JM; Guo XH; Yang WY; Weng JP; Jia WP; Zou DJ; Zhou ZG; Yu DM; Liu J; Shan ZY; Yang YZ; Hu RM; Zhu DL; Yang LY; Chen L; Zhao ZG; Li QF; Tian HM; Ji QH; Liu J; Ge JP; Shi LX; Xu YC
    BMC Public Health; 2013 Jun; 13():602. PubMed ID: 23800082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.
    Falcetta P; Nicolì F; Citro F; Ciccarone A; Garofolo M; Del Prato S; Bianchi C
    Acta Diabetol; 2023 Jan; 60(1):53-60. PubMed ID: 36166172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
    Peng XV; McCrimmon RJ; Shepherd L; Boss A; Lubwama R; Dex T; Skolnik N; Ji L; Avogaro A; Blonde L
    Diabetes Ther; 2020 Nov; 11(11):2629-2645. PubMed ID: 32902774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.
    Hall GC; McMahon AD; Dain MP; Wang E; Home PD
    Diabet Med; 2013 Jun; 30(6):681-6. PubMed ID: 23330649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States.
    Durden E; Liang M; Fowler R; Panton UH; Mocevic E
    J Manag Care Spec Pharm; 2019 Jun; 25(6):669-680. PubMed ID: 30896359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.
    Ken-Opurum J; Srinivas SSS; Jain D; Shah T; Samnaliev M; Dex T; Charland S; Revel A; Preblick R
    Diabetes Ther; 2023 Dec; 14(12):2109-2125. PubMed ID: 37801225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world impact on monthly glucose-lowering medication cost, HbA
    Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT
    J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensification patterns and the probability of HbA
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman JM; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
    Diabet Med; 2020 Jul; 37(7):1114-1124. PubMed ID: 30653705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
    Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
    Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Metabolic Changes in Patients With Type 2 Diabetes on High-Dose Insulin.
    Rentsch T; Awad M; Moorman JM; Gothard MD
    Am J Ther; 2022 Nov-Dec 01; 29(6):e632-e636. PubMed ID: 33416240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes.
    Korytkowski MT; Brooks M; Lombardero M; DeAlmeida D; Kanter J; Magaji V; Orchard T; Siminerio L
    J Diabetes Sci Technol; 2015 May; 9(3):593-601. PubMed ID: 25526759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries.
    Hartmann B; Lanzinger S; van Mark G; Wosch FJ; Durmaz M; Plaumann M; Sziegoleit S; Seufert J; Holl RW; Bramlage P;
    Acta Diabetol; 2020 Feb; 57(2):229-236. PubMed ID: 31471633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.